CRY

CryoLife, Inc.

NYSE

Add Alert

CRY

CryoLife, Inc.

NYSE

Add Alert

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Live Updating

chriswolff Terminated

07/25/17 6:00 AM

Post #24

This ticker is making a habit of beating EPS and revenue guidance consistently. Targeting $25 today!

4Godnwv

05/29/15 5:16 PM

Post #23

Re: #22: @4Godnwv - Oops, forgot to post - In CRY on

Out CRY 10.77 -.08

4Godnwv

05/27/15 7:56 PM

Post #22

Oops, forgot to post - In CRY on 5/18 @ 10.85

UserAlias1 Free

02/17/15 6:48 AM

Post #21

Re: #19: @Penny Roger$ - <<< $CRY Links! >>> ~ MAC's Quick DD

CryoLife Fourth-Quarter-Revenues Increase 5-Percent to $37.2 Million; Full Year Revenues Increase 3 Percent to $144.6 Million

Last update: 17/02/2015 6:34:06 am

CryoLife Fourth Quarter Revenues Increase 5 Percent to $37.2 Million; Full Year Revenues Increase 3 Percent to $144.6 Million

PR Newswire

ATLANTA, Feb. 17, 2015

ATLANTA, Feb. 17, 2015 /PRNewswire/ --

Financial and Recent Highlights:
-- Product revenues grew 12 percent for the quarter and 7 percent for the
full year

-- BioGlue(R) revenues grew 11 percent for the quarter and 7 percent for the
full year

-- HeRO(R) revenues grew 10 percent for the quarter and 24 percent for the
full year

-- PerClot(R) revenues grew 52 percent for the quarter and 23 percent for
the full year

-- Tissue processing revenues decreased 4 percent for the quarter and 3
percent for the full year

-- Launched ProCol(R) and PhotoFix(TM)

-- On track to begin enrollment in PerClot IDE clinical trial in the first
quarter of 2015

CryoLife, Inc. (NYSE: CRY), a leading medical device and tissue processing company focused on cardiac and vascular surgery, announced today its results for the fourth quarter and full year of 2014. Revenues for the fourth quarter of 2014 increased 5 percent to $37.2 million compared to $35.5 million for the fourth quarter of 2013. Revenues for the full year of 2014 increased 3 percent to $144.6 million compared to $140.8 million for the full year of 2013.

Pat Mackin, President and Chief Executive Officer, said, "CryoLife had a solid fourth quarter, with double-digit revenue growth for our key medical device products, partially offset by a decline in tissue processing revenues. During the quarter we launched ProCol, followed by the launch of PhotoFix in January, adding two new key products that further leverage our sales force and strong customer relationships. We also made good progress with our pipeline initiatives and remain positioned to begin enrollment in the PerClot IDE clinical trial during the first quarter of 2015. Outside of the U.S., we remain on track with our regulatory efforts to expand the indication for BioGlue in Japan later in 2015. Altogether, this puts us in a good position in the long-term to significantly expand our higher margin medical device revenues, which continue to represent a larger mix of our overall business."

Mr. Mackin continued, "In 2015 we are investing in several strategic initiatives to enhance the long-term growth and margin expansion potential of our business. This includes the PerClot IDE trial, enhanced quality and regulatory controls for our tissue processing business, and plans to transition to a direct sales organization in one of our European territories. We also have ongoing litigation regarding PerClot that we believe is important to protect our investments in the IDE trial and future market opportunities. While these initiatives will impact our revenue growth and profitability in 2015, we believe they strongly position the Company for improved performance beginning in 2016."

Net income for the fourth quarter of 2014 was $1.8 million, or $0.06 per basic and per fully diluted common share, compared to net income of $9.0 million, or $0.33 per basic and $0.31 per fully diluted common share, for the fourth quarter of 2013. Excluding certain items as shown in the schedules below, proforma non-GAAP fully diluted earnings per share was $0.04 in the fourth quarter of 2014, compared to $0.07 in the fourth quarter of 2013.

Net income for the full year of 2014 was $7.3 million, or $0.26 per basic and $0.25 per fully diluted common share, compared to net income of $16.2 million, or $0.59 per basic and $0.57 per fully diluted common share, for the full year of 2013. Excluding certain items as shown in the schedules below, proforma non-GAAP fully diluted earnings per share was $0.18 for the full year of 2014, compared to $0.33 in 2013.

Product revenues were $21.7 million for the fourth quarter of 2014, up 12 percent from $19.4 million in the fourth quarter of 2013. Product revenues were $81.9 million for the full year of 2014, up 7 percent from $76.2 million in the full year of 2013.

Surgical sealant and hemostat revenues, which consisted primarily of sales of BioGlue and PerClot, were $17.6 million for the fourth quarter of 2014 compared to $15.6 million for the fourth quarter of 2013, an increase of 13 percent. Surgical sealant and hemostat revenues were $66.4 million for the full year of 2014 compared to $61.5 million for the full year of 2013, an increase of 8 percent. The increase in surgical sealant and hemostat revenues for the fourth quarter and full year of 2014 was due to an increase in BioGlue unit shipments into both domestic and international markets, and to a lesser extent, an increase in BioGlue average sales prices and an increase in PerClot unit shipments.

HeRO Graft revenues were $1.8 million for the fourth quarter of 2014 compared to $1.7 million in the fourth quarter of 2013, an increase of 10 percent. HeRO Graft revenues were $7.1 million for the full year of 2014 compared to $5.7 million for the full year of 2013, an increase of 24 percent.

CardioGenesis cardiac laser therapy revenues were $2.2 million for the fourth quarter of 2014 compared to $2.1 million for the fourth quarter of 2013. Cardiac laser therapy revenues were $8.2 million for the full year of 2014 compared to $9.0 million for the full year of 2013. The increase in cardiac laser therapy revenues for the fourth quarter of 2014 was primarily due to an increase in handpiece shipments, partially offset by a decrease in laser console shipments, while the decrease in the full year of 2014 was primarily due to a decrease in laser console and handpiece shipments.

Preservation services revenues were $15.5 million for the fourth quarter of 2014 compared to $16.1 million for the fourth quarter of 2013, a decrease of 4 percent. Cardiac preservation service revenues for the fourth quarter of 2014 were flat compared to the fourth quarter of 2013 and included a decrease in unit shipments, offset by an increase in average service fees. Vascular preservation services revenues decreased 7 percent for the fourth quarter of 2014 compared to the fourth quarter of 2013 due to decreases in unit shipments of vascular tissues, partially offset by an increase in average service fees.

Preservation services revenues were $62.8 million for the full year of 2014 compared to $64.5 million for the full year of 2013, a decrease of 3 percent. Cardiac preservation service revenues in the full year of 2014 were flat compared to the full year of 2013 and included a decrease in unit shipments of cardiac grafts, offset by an increase in average service fees. Vascular preservation services revenues decreased 5 percent for the full year of 2014 compared to the full year of 2013 due to a decrease in unit shipments of vascular grafts, partially offset by an increase in average service fees.

Total gross margins were 61 percent in the fourth quarter of 2014 compared to 63 percent in the fourth quarter of 2013. Product gross margins were 77 percent for the fourth quarters of 2014 and 2013. Preservation services gross margins were 39 percent and 46 percent in the fourth quarters of 2014 and 2013, respectively.

Total gross margins were 63 percent and 64 percent in the full year of 2014 and 2013, respectively. Product gross margins were 79 percent and 80 percent for the full year of 2014 and 2013, respectively. Preservation services gross margins were 42 percent and 45 percent in the full year of 2014 and 2013, respectively. The decrease in preservation services gross margin was primarily related to lower processing throughput of tissues, increased compliance and personnel costs, and an increase in the cost of materials for tissues shipped during the fourth quarter and full year of 2014.

General, administrative, and marketing expenses for the fourth quarters of 2014 and 2013 were $18.6 million and $16.7 million, respectively. General, administrative, and marketing expenses for the full year of 2014 and 2013 were $73.8 million and $68.1 million, respectively. General, administrative, and marketing expenses for the fourth quarter and full year of 2014 included approximately $565,000 and $2.0 million, respectively, in pretax compensation charges related to personnel changes.

Research and development expenses were $2.1 million and $2.5 million for the fourth quarters of 2014 and 2013, respectively. Research and development expenses were $8.7 million and $8.5 million for the full year of 2014 and 2013, respectively. Research and development spending in 2014 was focused on PerClot, tissue processing, and BioGlue and BioFoam(R) .

For the full year of 2014, the Company purchased 585,000 shares of its common stock under the repurchase program that expired in October 2014 at an average price of $9.55 per share, resulting in aggregate purchases of $5.6 million.

As of December 31, 2014, the Company had $39.3 million in cash, cash equivalents, and restricted cash and securities, compared to $43.0 million at December 31, 2013. Of this $39.3 million in cash, cash equivalents, and restricted cash and securities, $5.9 million was designated as restricted cash and securities, primarily due to a financial covenant requirement under the Company's credit agreement. The Company's net cash flows provided by operations were $4.8 million for the fourth quarter of 2014 compared to $5.5 million for the fourth quarter of 2013. The Company's net cash flows provided by operations were $8.1 million for the full year of 2014 compared to $16.8 million for the full year of 2013.

(MORE TO FOLLOW) Dow Jones Newswires

February 17, 2015 06:34 ET (11:34 GMT)

surf1944

05/15/12 2:40 PM

Post #20

8:06AM CryoLife to acquire Hemosphere for $17 mln in cash, plus potential revenue milestone-based payments of up to $4.5 mln (CRY) 4.92 : Co announced today that it has signed a definitive agreement to acquire Hemosphere, Inc., a privately-held medical device company that has developed and markets the HeRO (Hemodialysis Reliable Outflow) Graft. The HeRO Graft is a proprietary graft-based solution for end-stage renal disease (ESRD) hemodialysis patients with limited access options and central venous obstruction. Under terms of the agreement, CryoLife will acquire Hemosphere for $17.0 mln in cash, plus potential revenue milestone-based payments of up to $4.5 mln. CryoLife intends to use cash on hand to finance the transaction, which is expected to close in May. Hemosphere's revenues were $5.3 mln and gross margins were 65.6 percent for the full year 2011. Assuming the transaction closes in May as anticipated, the Company expects revenues of between $2.5 mln and $3.5 mln for the Hemosphere product line in 2012. The Company expects to incur between $0.09 and $0.10 per share in charges in 2012 related to the acquisition of Hemosphere, which includes non-recurring transaction and integration charges of between $0.06 and $0.08 per share, with between $0.04 and $0.05 per share of those estimated transaction and integration charges to occur during the second quarter. The Company anticipates that the transaction will be slightly dilutive to earnings to break even for 2013. The above per share charges assume a 35 percent income tax rate. However, due to the non-deductibility of certain transaction expenses, the Company expects its income tax rate in the second quarter of 2012 to be higher than 35 percen

Penny Roger$ Free

04/26/12 7:38 AM

Post #19

Re: #18: @Penny Roger$ - ~ Thursday! $CRY ~ Q1 Earnings posted, pending

Penny Roger$ Free

04/26/12 7:38 AM

Post #18

~ Thursday! $CRY ~ Q1 Earnings posted, pending or coming soon! In Charts and Links Below!

~ $CRY ~ Earnings expected on Thursday *
Want more like this? Search Keyword: MACMONEY >>> http://tinyurl.com/MACMONEY <<<
One or more of many earnings sites has alerted this security has or will be posting earnings on or around the day of this message.

http://stockcharts.com/h-sc/ui?s=CRY&p=D&b=3&g=0&id=p88783918276&a=237480049

http://stockcharts.com/h-sc/ui?s=CRY&p=W&b=3&g=0&id=p54550695994

~ Google Finance: http://www.google.com/finance?q=CRY
~ Google Fin Options: hhttp://www.google.com/finance/option_chain?q=CRY#
~ Yahoo! Finance ~ Stats: http://finance.yahoo.com/q/ks?s=CRY+Key+Statistics
~ Yahoo! Finance ~ Profile: http://finance.yahoo.com/q/pr?s=CRY
Finviz: http://finviz.com/quote.ashx?t=CRY
~ BusyStock: http://busystock.com/i.php?s=CRY&v=2

<<<<<< http://www.earningswhispers.com/stocks.asp?symbol=CRY >>>>>>

http://investorshub.advfn.com/boards/post_prvt.aspx?user=251916

*If the earnings date is in error please ignore error. I do my best.

tradingtornadodotcom Free

03/23/12 11:04 AM

Post #17

Today I recommend buying CRY and shorting WMGI against it. This spread has the potential to make you a 10-20% spread return.

Joshua22

02/24/12 9:42 AM

Post #16

Cryo$

Penny Roger$ Free

02/10/12 4:29 AM

Post #15

~ Monday! $CRY ~ Earnings posted, pending or coming soon! In Charts and Links Below!

~ $CRY ~ Earnings expected on Monday *
Want more like this? Search Keyword: MACMONEY >>> http://tinyurl.com/MACMONEY <<<
One or more of many earnings sites has alerted this security has or will be posting earnings on or around the day of this message.

http://stockcharts.com/h-sc/ui?s=CRY&p=D&b=3&g=0&id=p88783918276&a=237480049

http://stockcharts.com/h-sc/ui?s=CRY&p=W&b=3&g=0&id=p54550695994

~ Google Finance: http://www.google.com/finance?q=CRY
~ Google Fin Options: hhttp://www.google.com/finance/option_chain?q=CRY#
~ Yahoo! Finance ~ Stats: http://finance.yahoo.com/q/ks?s=CRY+Key+Statistics
~ Yahoo! Finance ~ Profile: http://finance.yahoo.com/q/pr?s=CRY
Finviz: http://finviz.com/quote.ashx?t=CRY
~ BusyStock: http://busystock.com/i.php?s=CRY&v=2

<<<<<< http://www.earningswhispers.com/stocks.asp?symbol=CRY >>>>>>

http://investorshub.advfn.com/boards/post_prvt.aspx?user=251916

*If the earnings date is in error please ignore error. I do my best.

mkendra

02/01/12 12:50 PM

Post #14

Looking at this.

tekor

08/26/11 12:31 PM

Post #13

Nice 2.6% jump up .12 for the day

tekor

08/25/11 10:58 PM

Post #10

Re: #9: @tekor - rebound tomorrow. CRY

CRY is under radar!

tekor

08/25/11 6:26 PM

Post #9

rebound tomorrow. CRY

tekor

08/25/11 2:22 PM

Post #6

cheap buys

tekor

08/25/11 2:22 PM

Post #5

this will go to $8 soon

lightbeam

04/29/11 10:26 PM

Post #4

Re: #3: @lightbeam - Looking to turn around now.

lightbeam

02/02/11 2:37 PM

Post #3

Re: #2: @Bad cuda - looking for 8.00 by xmas, great chart!!!! The

Looking to turn around now.

Bad cuda

10/13/10 2:31 PM

Post #2

looking for 8.00 by xmas, great chart!!!! The 6.20 break says it all.

TradetheChart f/k/a Mike Butler Terminated

02/10/08 5:42 PM

Post #1

Major mover last week!

CryoLife, Inc. (CRY)

Followers	4	Posters	12
Posts (Today)	0	Posts (Total)	24
Created	02/10/08	Type	Free
Moderators

CryoLife, Inc. (CryoLife) develops and commercializes biomaterials, implantable medical devices, and preserves and distributes human tissues for cardiovascular and vascular transplant applications. The Company's biomaterials and implantable devices include BioGlue Surgical Adhesive (BioGlue), porcine heart valves and vascular grafts of bovine tissue processed using the Company's SynerGraft technology. CryoLife distributes a porcine heart valve, the CryoLife O'Brien aortic heart valve in Europe, the Middle East and Africa (EMEA). CryoLife also markets its SynerGraft bovine vascular graft, the SynerGraft Model 100, in the EMEA.

Corporate Update

During the first quarter of 2010 CryoLife management embarked on an aggressive corporate acquisition strategy to strengthen the company's product offerings in the areas of cardiovascular and vascular surgery. The Company has been able to implement this strategy due to the unusual economic conditions that presently exist in the U.S. financial markets related to the lack of funding that is available for new technologies and start-up companies. CryoLife's unique cash flow position and our ability to access working capital have given us the opportunity to acquire and fund new technologies that are under development or acquire and fund small companies unable to successfully access U.S. capital markets.

Additionally, management's thinking behind this strategy was based upon the fact that the aging U.S. population, 78 million "baby boomers," would increasingly be confronted by complications from cardiovascular diseases. Historically, the company has focused on unique products for the treatment of complex cardiac and vascular reconstruction procedures. It was management's thinking that expanding the treatment options for people with cardiac and vascular issues would enable us to bring life and limb saving technologies to more people throughout the world.

To that end, in September of 2010, CryoLife signed a manufacturing and distribution agreement with Starch Medical, Inc., of San Jose, California, for PerClot®, a powdered hemostat that they were marketing in Europe. This agreement helps solidify our participation in a worldwide market for powdered hemostats that industry analysts estimate to be about $2 billion. Our agreement covers the entire world except for China and certain Middle Eastern countries. PerClot is CE Marked for distribution in many European countries at this time. CryoLife has conducted animal trials and biocompatibility testing and submitted its investigational device exemption, or IDE to the FDA at the end of March 2011. PerClot is not approved for use in the U.S. at this time.

PerClot is a complementary product to our surgical adhesive BioGlue® that has been available for clinical use since 1998 and has been used in over 615,000 surgical procedures throughout the world. PerClot may be used in wet surgical fields and initiates hemostasis immediately when it is confronted by blood from a wound. In tests conducted in our research laboratory it appears that PerClot absorbs two to three times as much water as the other powdered hemostats that are commercially available.

In May of 2011 the company completed the acquisition of Cardiogenesis corporation. Cardiogenesis, a wholly owned subsidiary of CryoLife, Inc., is a pioneer in the development and use of laser technology for transmyocardial revascularization (TMR) in patients with severe or refractory angina. It is approved by the FDA for distribution in the U.S. and is CE Marked for use in Europe. It is a Medicare approved therapy and is reimburseable. TMR is accepted as a meaningful therapy and treatment for refractive angina by the American College of Cardiology, American Heart Association and the Society of Thoracic Surgery. Cardiogenesis has a CE Mark for the use of autogenous (the patient's own) stem cells in conjunction with TMR.

CryoLife management is excited by the acquisition of Cardiogenesis. The company almost doubled its sales force focused on cardiac surgeons upon closing the transaction. Cardiogenesis' revenues in 2010 were $11.3 million.

Calendar year 2010 proved to be a very successful year for CryoLife. We set all time fourth quarter and full year revenue records of $29.2 million and $116.6 million, respectively, for the periods ending December 31, 2010. Net income for the full year of 2010 was $3.9 million, or $0.14 cents per basic and fully diluted share. Another indicator of the company's ability to thrive in a difficult economy was that we generated operating cash flow of $7 million in the fourth quarter and $20.8 million for the year ended December 31, 2010.

For a more detailed discussion of the company's operations, products and services you may request a copy of the company's Annual Report on Form 10-K for 2010 or you may view it on the company's website by clicking on Investor Relations.

Very truly yours,

Steven G. Anderson
Founder, President and CEO
Atlanta, Georgia